StonkFun's token price fell over 16% after reaching a peak of $0.35, entering a correction phase marked by a downtrend and weakening support levels. The decline is linked to reduced trading volumes across Spot, Futures, and DEX markets, alongside a significant drop in daily protocol fees, signaling weakening network activity. Despite this, STONK still generates more revenue than some competitors, suggesting potential for recovery if it can sustain supply reductions through token burns. The token's price will be closely watched around the 100 EMA support level to determine if it can rebound or continue declining to lower price zones.
StonkFun's token price correction phase is the subject, with Pluang market data providing context. As of Sep 16, 2026 04:52 WIB, only 4 of 50 major cryptocurrencies rose while 45 fell. Notable movers include SXP down 46.27%, FIL down 13.87% with 70% sell order activity, and BAL up 11.14%.
Acoramidis, a drug for transthyretin amyloid cardiomyopathy (ATTR-CM), was linked to an 18% lower risk of death, hospitalization, and disease progression compared to tafamidis in a large U.S. electronic health record study of 2,684 patients. The stud...
Stellantis revealed six concept cars from its iconic brands at an exclusive event before the Paris Motor Show, highlighting its FaSTLAne 2030 strategy focused on innovation, customer experience, and diverse mobility solutions. These concepts, includi...
Freenome announced improved clinical validation results for its updated SimpleScreen™ CRC blood test, showing an 18.2% sensitivity for advanced precancerous lesions (APLs), up from 13.7% in the original test. Sensitivity for high-grade dysplasia APLs...
The European Union is consulting on whether developers of noncustodial Bitcoin wallets should require certification before releasing their software publicly. This review is part of a broader assessment of the EU's Markets in Crypto-Assets Regulation ...
BridgeBio Pharma announced that encaleret, a treatment for autosomal dominant hypocalcemia type 1 (ADH1), increased bone turnover and improved patient-reported symptoms in the Phase 3 CALIBRATE trial. 100% of patients on encaleret reported symptom im...
